Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody(tm) platform, is pleased to announce that it has signed a deal with Cobra Biomanufacturing Plc (`Cobra Biomanufacturing') for Good Manufacturing Practice (`GMP') manufacture of its SCIB1 DNA vaccine. Scancell plan to commence clinical trials of SCIB1 in the UK in 1Q2010.

Scancell is developing SCIB1, a DNA vaccine for the potential treatment of late-stage melanoma cancer patients. There are 8000 new cases of melanoma every year in the UK with 1800 deaths per year. Early stage melanoma is often cured by surgery but advanced disease has a very poor prognosis with late stage (stage IV) disease having a median survival of approximately 6 months. SCIB1 was developed using Scancell's ImmunoBody(tm) technology and is engineered to express the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In animal models, SCIB1 prevented the development of lung metastases and significantly inhibited the growth of established tumours.

Cobra Biomanufacturing is an AIM-listed contract manufacturer of biopharmaceuticals that is compliant with cGMP standards worldwide.

David Evans, chairman of Scancell, commented:

"We are delighted to sign a deal with Cobra Biomanufacturing to manufacture our SCIB1 DNA vaccine. That we are commencing GMP manufacture of SCIB1 on schedule is testament to the progress the Company continues to achieve."

Simon Saxby, Chief Executive of Cobra Biomanufacturing said:

"We are very pleased to be have been selected by Scancell as a result of Cobra's abilities and reputation as a leading cGMP compliant manufacturer of DNA. This agreement also underscores Cobra's long term commitment to the manufacture of therapeutic vaccines."

The Directors of the issuer accept responsibility for this announcement.  

The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’),
the developer of cancer vaccines based on its patented ImmunoBody™ platform, are pleased
to announce the interim results for Scancell for the six month period ended 31st October 2008
(‘the period’).

Highlights:

• Admitted to Plus markets on 24 September 2008 and raised £1.559,502 on 24th September 2008
• Issue of equity raised £43,999.8 on the 19th of December 2008
• Following the placing of shares in September, the Company has £2,220,479 cash reserves
• Continued make good progress towards its goal of starting Phase 1 clinical trials with SCIB1 in 2010
• Agreement to license key components of SCIB1 from National Institute for Health (‘NIH’) in the final phase of negotiation
• Negotiations to secure development and commercial rights to an injection device to deliver SCIB1 to patients progressing wel
• Experienced Development Advisor appointed for SCIB1
• Presented at the Genesis 2008 Oncology Showcase

David Evans, Non-Executive Chairman of Scancell, commented:

“I am delighted to report a very successful first six months as a public company. In 2008, we raised £1.6m in conjunction with being admitted to Plus markets. The funds raised will provide the ability to further develop Scancell’s core technology; the ImmunoBodyTM platform and to achieve its aim of starting Phase 1 clinical trials of SCIB1 in 2010.”

For further information contact:

Company:
Scancell Holdings Plc  -  Professor Lindy Durrant/Dr Richard Goodfellow  -  Tel: 020 7245 1100

Corporate Advisers:
St Helen's Capital Plc  -  Duncan Vasey/Barry Hocken  -  Tel: 020 7628 5582

Financial PR:
Hansard Group  -  Adam Reynolds/Vicky Krause  -  Tel: 020 7245 1100

View the full results

The Directors of Scancell are pleased to announce that on 19 December 2008, the Company issued 73,333 new ordinary shares of 1p each in lieu of advisory fees relating to the admission of the Company onto the PLUS-quoted market at a price of 60 pence per share.

The trading of the new ordinary shares on PLUS is expected to commence on 22 December 2008.

Following the issue of shares as detailed above the total number of ordinary shares in issue as at 19 December 2008 will be 10,275,551 ordinary shares. The total Directors' Shareholding as a result of the Issue of Equity is 2,627,892 ordinary shares representing 25.57% of the current issued share capital.

The Directors of the issuer accept responsibility for this announcement.

Notification of Interim Results

Scancell Holdings Plc, the developer of therapeutic cancer vaccines based on its patented ImmunoBody(tm) platform, today announces that it will release its Interim Results for the six months ended 31 October 2008 during the week commencing
Monday 12th January 2009.

The Directors of Scancell Holdings Plc are pleased to announce the audited results for Scancell Limited for the year ended 30 April 2008.

Chairman's Statement

In the last financial year we have consolidated our position in relation to the science and the finances of the Company.

In November, I was elected Non-Executive Chairman and brought my considerable experience in listed companies to the board. A decision was made at the beginning of 2008 to list the Company on the PLUS Market (www.PLUSmarketsgroup.com) and successfully achieved on the 24th of September 2008.This has attracted new finance to progress our lead product SCIB1 into the clinic and continue the development of the ImmunoBody platform. A decision was made by the directors that they are not paying a dividend for the period.

We look forward to updating shareholders with developments over the coming months.

For the full report click here

The admission announcement is available as a PDF. 

View announcement